| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
5-HT2A Receptor 5.3 nM (Ki) 5-HT2C Receptor 620 nM (Ki)
4F 4PP oxalate targets the serotonin 5-HT2A receptor. It is a selective antagonist with a Ki of 5.3 nM. The compound shows selectivity for 5-HT2A receptors over 5-HT1C (5-HT2C) receptors, with a Ki of 620 nM. It has almost as high affinity as ketanserin for 5-HT2A but with much lower affinity for 5-HT2C sites. By blocking 5-HT2A receptors, the compound modulates serotonergic signaling pathways involved in mood, perception, and cardiovascular function. |
|---|---|
| ln Vitro |
In vitro, 4F 4PP oxalate acts as a selective 5-HT2A receptor antagonist. Its activity is typically assessed by measuring its ability to inhibit agonist-induced calcium mobilization or inositol phosphate accumulation in cells expressing 5-HT2A receptors. The compound shows a Ki of 5.3 nM for 5-HT2A receptors and 620 nM for 5-HT1C receptors. Standard in vitro assays include receptor binding studies using radiolabeled ligands such as [3H]-ketanserin and functional assays measuring calcium signaling or phosphoinositide hydrolysis.
|
| ln Vivo |
In addition to producing a considerable depression of evoked field potentials, 4F 4PP (100 nM) lowers the lowest concentration of [D-ala2,N-me-phe4,gly.l5]-enkephalin (DAMGO)[1].
In vivo, 4F 4PP oxalate is used as a research tool to study 5-HT2A receptor function. As a selective 5-HT2A antagonist, it would be expected to modulate serotonergic signaling and affect behaviors related to mood, perception, and cognition. The compound's high affinity for 5-HT2A (Ki = 5.3 nM) and selectivity over 5-HT2C make it a valuable tool for dissecting the roles of 5-HT2 receptor subtypes. However, comprehensive in vivo efficacy data from published literature are limited. |
| Enzyme Assay |
For non-cell-based receptor binding assays, 4F 4PP oxalate can be evaluated using membrane preparations from cells expressing human 5-HT2A or 5-HT2C receptors. Radioligand binding displacement experiments are performed using suitable radiolabeled ligands such as [3H]-ketanserin for 5-HT2A or [3H]-mesulergine for 5-HT2C. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-90 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled ketanserin or mesulergine. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing human 5-HT2A receptors are cultured in appropriate media. For functional assays, intracellular calcium mobilization is measured using fluorescent calcium indicators such as Fluo-4 AM. Cells are loaded with the dye and pre-incubated with various concentrations of 4F 4PP oxalate. Receptor activation is stimulated by the addition of a 5-HT2A receptor agonist such as 5-HT or DOI. Fluorescence intensity is measured using a fluorescence plate reader. The reduction in calcium signal compared to control wells indicates antagonist activity. IC50 or pA2 values are calculated from dose-response curves.
|
| Animal Protocol |
For in vivo animal studies, 4F 4PP oxalate can be administered to rodents via intraperitoneal injection. In models of serotonin-mediated behaviors, its effects on locomotion, anxiety, and head-twitch response (a 5-HT2A-mediated behavior) are assessed. In models of psychiatric disorders, behavioral tests are conducted. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
4F 4PP oxalate has a molecular weight of 403.33 and a molecular formula of C17H17F4N3O4. It is a selective 5-HT2A antagonist with a Ki of 5.3 nM. The compound should be stored at -20°C for long-term stability. It is soluble in DMSO and can be formulated for both in vitro and in vivo administration. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 4F 4PP oxalate has not been extensively reported. As a 5-HT2A receptor antagonist, potential adverse effects may include modulation of serotonergic signaling, which could affect mood, perception, and cardiovascular function. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies.
|
| References |
[1]. Aira Z, et al. Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors. Pain. 2012;153(7):1418-1425.
[2]. Lee SH, et al. Peripheral serotonin receptor 2B and transient receptor potential channel 4 mediate pruritus to serotonergic antidepressants in mice. J Allergy Clin Immunol. 2018;142(4):1349-1352.e16. [3]. Rodríguez-Muñoz M, et al. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget. 2018;9(34):23373-23389. Published 2018 May 4. [4]. Gerhold KJ, et al. Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude. J Neurosci. 2015;35(26):9580-9594. |
| Additional Infomation |
4F 4PP oxalate (CAS 144734-36-1) is a selective antagonist of the serotonin 5-HT2A receptor. It exhibits a Ki of 5.3 nM for 5-HT2A receptors and shows selectivity over 5-HT1C receptors (Ki = 620 nM). It has almost as high affinity as ketanserin for 5-HT2A but with much lower affinity for 5-HT2C sites. It is available for research purposes only.
|
| Molecular Formula |
C24H28FNO5
|
|---|---|
| Molecular Weight |
429.48
|
| Exact Mass |
429.195
|
| CAS # |
144734-36-1
|
| PubChem CID |
24745966
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.836
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCCC3=CC=CC=C3.C(=O)(C(=O)O)O
|
| InChi Key |
VUJYJCRJPFMHEM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H26FNO.C2H2O4/c23-21-11-9-19(10-12-21)22(25)20-13-16-24(17-14-20)15-5-4-8-18-6-2-1-3-7-18;3-1(4)2(5)6/h1-3,6-7,9-12,20H,4-5,8,13-17H2;(H,3,4)(H,5,6)
|
| Chemical Name |
(4-fluorophenyl)-[1-(4-phenylbutyl)piperidin-4-yl]methanone;oxalic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 12.5 mg/mL (29.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.67 mg/mL (3.89 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (3.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3284 mL | 11.6420 mL | 23.2840 mL | |
| 5 mM | 0.4657 mL | 2.3284 mL | 4.6568 mL | |
| 10 mM | 0.2328 mL | 1.1642 mL | 2.3284 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
